Teladoc Health, Inc. — fact timeline

Michael Grasher was appointed as Chief Financial Officer at Teladoc Health, Inc..

“Effective August 31, 2026, Teladoc Health, Inc. (the “Company”) hired Michael Grasher as its Chief Financial Officer.”

Teladoc Health, Inc. shareholders approved Advisory Vote Approving the Compensation of the Company's Named Executive Officers at the 2026-05-21 meeting.

“Proposal 2 — Advisory Vote Approving the Compensation of the Company’s Named Executive Officers The stockholders of the Company approved, on an advisory basis, the compensation paid to the Company’s named executive officers. The voting results are set forth below. For Against Abstentions Broker Non-Votes 71,154,268 8,973,257 1,158,116 43,207,208”

Teladoc Health, Inc. shareholders approved Election of Directors at the 2026-05-21 meeting.

“Proposal 1 — Election of Directors The stockholders of the Company elected each of the following director nominees proposed by the Company’s Board of Directors to serve until the 2027 Annual Meeting of Stockholders of the Company and until their respective successors have been duly elected and qualified. The voting results for each director nominee are set forth below. Name For Against Abstentions Broker Non-Votes Charles Divita, III 76,534,562 4,688,083 62,996 43,207,208 Sandra L. Fenwick 74,876,294 5,374,184 1,035,163 43,207,208 Catherine A. Jacobson 73,823,862 6,428,082 1,033,697 43,207,208 Kenneth H. Paulus 74,670,036 6,524,629 90,976 43,207,208 Susan R. Salka 76,279,272 4,840,123 166,246 43,207,208 David L. Shedlarz 74,640,078 5,608,770 1,036,793 43,207,208 Mark Douglas Smith, M.D., MBA 78,213,920 2,011,677 1,060,044 43,207,208 Michael S. Smith 76,313,738 4,883,881 88,022 43,207,208 David B. Snow, Jr. 67,368,308 12,899,237 1,018,096 43,207,208”

Teladoc Health, Inc. reported the three months ended March 31, 2026 ("First Quarter 2026") results: revenue $613.8 million, net income $63.8 million, or $0.36 per share, EPS $0.36 per share. Guidance reaffirmed.

“First Quarter 2026 revenue of $613.8 million, down 2% year-over-year • First Quarter 2026 net loss of $63.8 million, or $0.36 per share”

Teladoc Health, Inc. incurred revolving credit of $300 million with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR plus a margin of 2.75% to 3.25% per annum maturing the fifth anniversary of the Effective Date.

“On July 17, 2025 (the “Effective Date”), Teladoc Health, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”), issuing bank and swingline lender, and the lenders party thereto. The Credit Agreement provides for a five-year, $300 million senior secured revolving credit facility (the “Revolving Credit Facility”).”

Michael Waters resigned as Chief Operating Officer at Teladoc Health, Inc..

“On September 27, 2024, Michael Waters, Chief Operating Officer of Teladoc Health, Inc. (the “Company”), resigned with good reason under his executive employment agreement with the Company in connection with a change in the Company's executive reporting structure.”

Joseph Catapano was appointed as Senior Vice President and Chief Accounting Officer at Teladoc Health, Inc..

“Effective September 9, 2024, Joseph Catapano joined Teladoc Health, Inc. (the “Company”) as its Senior Vice President and Chief Accounting Officer.”

Laizer Kornwasser departed as President, Enterprise Growth and Global Markets at Teladoc Health, Inc..

“On June 28, 2024, Teladoc Health, Inc. (the “Company”) terminated without cause the employment of Laizer Kornwasser, President, Enterprise Growth and Global Markets, in connection with a change in the Company's executive reporting structure, effective July 1, 2024.”

Mala Murthy changed role as Chief Financial Officer at Teladoc Health, Inc..

“Mala Murthy stepped down as acting Chief Executive Officer of the Company and will remain the Company's Chief Financial Officer.”

Charles Divita, III was appointed as Director at Teladoc Health, Inc..

“appointed Mr. Divita as a director of the Company.”

Charles Divita, III was appointed as Chief Executive Officer at Teladoc Health, Inc..

“Charles Divita, III joined Teladoc Health, Inc. (the “Company”) as its Chief Executive Officer.”

Teladoc Health, Inc. reported three months ended March 31, 2024 results: revenue $646.1 million, net income $81.9 million net loss, EPS $0.49 per share. Guidance reaffirmed.

“the three months ended March 31, 2023 (“First Quarter 2023”). Financial and Operational Highlights for First Quarter 2024 • First Quarter 2024 revenue grows 3% year-over-year to $646.1 million • First Quarter 2024 net loss of $81.9 million, or $0.49 per share • First Quarter 2024 adjusted EBITDA of $63.1 million, up 20% year-over-year “We are pleased to report a solid”

James L. Cave was appointed as Interim Chief Accounting Officer at Teladoc Health, Inc..

“Upon Mr. Napolitano’s departure and until such time as a permanent replacement is named, Mr. James L. Cave, Vice President, Corporate Controller will assume his duties and responsibilities on an interim basis.”

Richard J. Napolitano resigned as Chief Accounting Officer at Teladoc Health, Inc..

“On April 8, 2024, Mr. Richard J. Napolitano, Chief Accounting Officer (Principal Accounting Officer) of Teladoc Health, Inc. (the “Company”) informed the Company of his decision to resign, effective May 3, 2024, to pursue another career opportunity.”

Teladoc Health, Inc. updated its quarter ended March 31, 2024 guidance (reaffirmed).

“On April 5, 2024, Teladoc Health, Inc. (“Teladoc Health” or the “Company”) announced that it continues to expect its outlook for the quarter ended March 31, 2024 and the year ending December 31, 2024 to be consistent with the outlook ranges disclosed in the Company’s earnings release on February 20, 2024. The financial results for the quarter ended March 31, 2024 are preliminary, unaudited and subject to change”

Mala Murthy was appointed as acting Chief Executive Officer at Teladoc Health, Inc..

“Teladoc Health announced the appointment of Mala Murthy to the position of acting Chief Executive Officer of the Company, effective immediately.”

Jason Gorevic departed as Chief Executive Officer at Teladoc Health, Inc..

“replacing Jason Gorevic, who will also depart from the Board of Directors of the Company as required by his employment agreement.”

Teladoc Health, Inc. reported the full year ended December 31, 2023 results: revenue $2,602.4 million, net income $220.4 million, EPS $1.34 per share. Guidance initiated.

“Teladoc Health Reports Fourth Quarter and Full Year 2023 Results • Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million • Fourth quarter 2023 net loss of $28.9 million, or $0.17 per share, and full year 2023 net loss of $220.4 million, or $1.34 per share”

Teladoc Health, Inc. reported the fourth quarter of 2023 results: revenue $660.5 million, net income $28.9 million, EPS $0.17 per share. Guidance initiated.

“$ (84.60) 98 % Adjusted EBITDA (1) $ 114,443 $ 94,094 22 % $ 328,120 $ 246,513 33 % See note (1) in the Notes section that follows. 1 Fourth Quarter 2023 Revenue increased 4% to $660.5 million from $637.7 million in the fourth quarter of 2022. Access fees revenue grew 4% to $573.9 million and other revenue grew 3% to $86.6 million. U.S. revenue grew 2% to $564.8”

Claus T. Jensen resigned as Chief Innovation Officer at Teladoc Health, Inc..

“On November 8, 2023, Claus T. Jensen, PhD resigned as Chief Innovation Officer of Teladoc Health, Inc. (the “Company”), effective December 1, 2023 (the “Separation Date”).”

Teladoc Health, Inc. reported the third quarter of 2023 results: revenue $660.2 million, net income $57.1 million, EPS $0.35 per share.

“Teladoc Health Reports Third Quarter 2023 Results • Third quarter 2023 revenue grows 8% year-over-year to $660.2 million • Third quarter 2023 operating cash flow of $105.6 million; free cash flow of $68.0 million • Third quarter 2023 net loss of $57.1 million, or $0.35 per share • Third quarter 2023 adjusted EBITDA of $88.8 million, up 73% year-over-year”

J. Eric Evans was appointed as director at Teladoc Health, Inc..

“Effective September 20, 2023, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed J. Eric Evans as a director of the Company.”

Teladoc Health, Inc. reported Year ending December 31, 2023 results: revenue $2,600 - $2,675 million, EPS ($1.60) - ($1.25) loss per share. Guidance initiated.

“For the year ending December 31, 2023, we expect: Full Year 2023 Outlook Range Revenue $2,600 - $2,675 million”

Teladoc Health, Inc. reported Third quarter 2023 results: revenue $650 - $675 million, EPS ($0.50) - ($0.40) loss per share. Guidance initiated.

“For third quarter 2023, we expect: 3Q 2023 Outlook Range Revenue $650 - $675 million”

Teladoc Health, Inc. reported Six Months Ended June 30, 2023 results: revenue $1,281.7 million, net income $134.4 million loss, EPS $0.82 loss per share.

“quarter 2022. Adjusted gross margin (1) was 70.8% for second quarter 2023, compared to 69.2% for second quarter 2022. Six Months Ended June 30, 2023 Revenue increased 11% to $1,281.7 million from $1,157.7 million in the first half of 2022. Access fees revenue grew 12% to $1,126.5 million, and other revenue grew 5% to $155.1 million. U.S. revenue grew 9% to $1,103.4”

Teladoc Health, Inc. shareholders rejected Stockholder Proposal Entitled “Fair Elections”.

“Proposal 6 — Voting on a Stockholder Proposal Entitled “Fair Elections” The stockholders of the Company did not approve a stockholder proposal entitled “Fair Elections”. The voting results are set forth below. For Against Abstentions Broker Non-Votes 14,994,415 75,977,425 358,166 28,923,619”

Teladoc Health, Inc. shareholders approved Ratifying the Appointment of the Independent Registered Public Accounting Firm at the 2023-12-31 meeting.

“Proposal 5 — Ratifying the Appointment of the Independent Registered Public Accounting Firm The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results are set forth below. For Against Abstentions Broker Non-Votes 118,869,979 757,876 625,770 N/A”

Teladoc Health, Inc. shareholders approved Approving an Amendment to the Teladoc Health, Inc. 2015 Employee Stock Purchase Plan.

“Proposal 4 — Approving an Amendment to the Teladoc Health, Inc. 2015 Employee Stock Purchase Plan The stockholders of the Company approved an amendment to the Teladoc Health, Inc. 2015 Employee Stock Purchase Plan. The voting results are set forth below. For Against Abstentions Broker Non-Votes 90,596,731 615,655 117,620 28,923,619”

Teladoc Health, Inc. shareholders approved Approving the Teladoc Health, Inc. 2023 Incentive Award Plan.

“Proposal 3 — Approving the Teladoc Health, Inc. 2023 Incentive Award Plan The stockholders of the Company approved the Teladoc Health, Inc. 2023 Incentive Award Plan. The voting results are set forth below. For Against Abstentions Broker Non-Votes 51,690,454 39,506,673 132,879 28,923,619”

Teladoc Health, Inc. shareholders approved Advisory Vote Approving the Compensation of the Company’s Named Executive Officers.

“Proposal 2 — Advisory Vote Approving the Compensation of the Company’s Named Executive Officers The stockholders of the Company approved, on an advisory basis, the compensation paid to the Company’s named executive officers. The voting results are set forth below. For Against Abstentions Broker Non-Votes 74,437,080 16,406,746 486,180 28,923,619”

Teladoc Health, Inc. shareholders approved Election of Directors.

“Proposal 1 — Election of Directors The stockholders of the Company elected each of the following director nominees proposed by the Company’s Board of Directors to serve until the 2024 Annual Meeting of Stockholders of the Company and until their respective successors have been duly elected and qualified. The voting results for each director nominee are set forth below. Name For Against Abstentions Broker Non-Votes Karen L. Daniel 90,139,425 949,292 241,289 28,923,619 Sandra L. Fenwick 89,927,780 1,173,491 228,735 28,923,619 Jason Gorevic 90,172,443 924,178 233,385 28,923,619 Catherine A. Jacobson 90,113,407 975,068 241,531 28,923,619 Thomas G. McKinley 86,075,780 5,004,803 249,423 28,923,619 Kenneth H. Paulus 89,421,095 1,657,837 251,074 28,923,619 David L. Shedlarz 88,399,631 2,682,261 248,114 28,923,619 Mark Douglas Smith, M.D., MBA 89,898,033 1,180,486 251,487 28,923,619 David B. Snow, Jr. 86,958,904 4,162,296 208,806 28,923,619”

Teladoc Health, Inc. reported first quarter ended March 31, 2023 results: revenue $629.2 million, net income Net loss of $69.2 million, EPS $0.42 per share. Guidance initiated.

“● First quarter 2023 revenue grows 11% year-over-year to $629.2 million ● First quarter 2023 net loss of $69.2 million, or $0.42 per share ● First quarter adjusted EBITDA totaled $52.8 million”

Teladoc Health, Inc. reported Full Year 2022 results: revenue $2,406.8 million, net income ($13,659.5 million), EPS ($84.60) per share.

“Full Year Ended December 31, 2022 Revenue increased 18% to $2,406.8 million from $2,032.7 million for the year ended December 31, 2022 (“Full-Year 2022”). Access fees revenue grew 21% to $2,103.8 million, and other revenue grew 4% to $303.0 million. U.S. revenues and International revenues each grew 18% to $2,101.0 million and $305.8 million, respectively. Revenue increased 6% to $1,373.9 million for the Integrated Care segment and increased 41% to $1,019.6 million for the BetterHelp segment for Full-Year 2022. Non-cash goodwill impairment charges of $13.4 billion were recorded for Full-Year 2022. The non-cash charges had no impact on the provision for income taxes. Net loss totaled $13,659.5 million, or ($84.60) per share, for the year ended December 31,2022, compared to $428.8 million, or ($2.73) per share, for the year ended December 31, 2021.”

Teladoc Health, Inc. reported Fourth Quarter 2022 results: revenue $637.7 million, net income ($3,810.1 million), EPS ($23.49) per share.

“Fourth Quarter 2022 Revenue increased 15% to $637.7 million from $554.2 million in the fourth quarter of 2021. Access fees revenue grew 16% to $553.7 million and other revenue grew 10% to $84.0 million. U.S. Revenues grew 15% to $554.4 million and International revenues grew 17% to $83.3 million. Revenue increased 6% to $357.1 million for the Teladoc Health Integrated Care (“Integrated Care”) segment and increased 29% to $277.0 million for the BetterHelp segment in the fourth quarter of 2022. See note (9) in the Notes section that follows for further information regarding segment reporting. Non-cash goodwill impairment charges of $3.8 billion were recorded in the fourth quarter of 2022. The non-cash charges had no impact on the provision for income taxes. Net loss totaled $3,810.1 million, or ($23.49) per share, for the fourth quarter of 2022, compared to $11.0 million, or ($0.07) per share, for the fourth quarter of 2021.”

Teladoc Health, Inc. announced a restructuring with charges of approximately $17 million in pre-tax charges in 2023 affecting the Company (approximately 6 percent).

“On January 18, 2023, Teladoc Health, Inc. (the “Company”) announced a restructuring plan intended to reduce operating costs. In addition, the Company underwent certain other cost-saving actions taken during the latter part of the fourth quarter of 2022. The combination of these actions results in a reduction of the Company’s workforce of approximately 6 percent, and office space reductions within certain markets.”

Laizer Kornwasser was appointed as President, Enterprise Growth and Global Markets at Teladoc Health, Inc..

“Effective October 24, 2022, Laizer Kornwasser joined Teladoc Health, Inc. (the “Company”) as its President, Enterprise Growth and Global Markets.”

Michael Waters was appointed as Chief Operating Officer at Teladoc Health, Inc..

“Effective July 25, 2022, Michael Waters joined Teladoc Health, Inc. (the “Company”) as its Chief Operating Officer.”

David Sides resigned as Chief Operating Officer at Teladoc Health, Inc..

“On September 17, 2021, Teladoc Health, Inc. (the “Company”) received notice from David Sides of his intention to resign as Chief Operating Officer of the Company effective on September 21, 2021, in order to pursue another employment opportunity.”